ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2110 • ACR Convergence 2022

    Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population

    Laure Gossec1, Mohamed Sharaf2, Elke Theander3, Marlies Neuhold4, Paul Bergmans5, May Shawi6, Michelle Perate7, Christine Contré8 and Laura Coates9, 1Sorbonne Université, Paris, France, 2Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 3Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen, Breda, Netherlands, 6Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
  • Abstract Number: 2114 • ACR Convergence 2022

    Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study

    Iain B McInnes1, Enrique R Soriano2, Lai-shan Tam3, Natalie Shiff4, May Shawi5, Emmanouil Rampakakis6 and Jeffrey Curtis7, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7University of Alabama at Birmingham, Division of Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…
  • Abstract Number: 2115 • ACR Convergence 2022

    Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study

    Laura Coates1, Julio Ramírez2, Dennis McGonagle3, Sibel Aydin4, Miriam Zimmermann5, Francois Nantel6, May Shawi7, Emmanouil Rampakakis8, Peter Nash9 and Philip J Mease10, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 2Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain, 3University of Leeds, Leeds, UK, Leeds, United Kingdom, 4University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, 6Nantel MedSci Consult, Montréal, QC, Canada, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9School of Medicine, Griffith University, Sunshine Coast, Australia, 10Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended…
  • Abstract Number: 2109 • ACR Convergence 2022

    Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Arthur Kavanaugh1, Gordon Lam2, Lai-shan Tam3, Natalie Shiff4, Youngja Lee5, Ana-Maria Bravo Perdomo6, May Shawi7, Elizabeth Hsia8, Emmanouil Rampakakis9 and Carlos Enrique Toro Gutiérrez10, 1University of California San Diego, La Jolla, CA, 2Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, 5Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, 6Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, 9McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 10Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia

    Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
  • Abstract Number: 2032 • ACR Convergence 2022

    Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

    Kunal Chandwar1, Juhi Dixit1, Kriti Kishor1, DOGGA PRASANNA KUMAR2, DIGVIJAY EKBOTE3, PUNEET KUMAR1 and Urmila Dhakad1, 1King George's Medical University, Lucknow, India, 2KGMU, LUCKNOW, Uttar Pradesh, India, 3KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India

    Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
  • Abstract Number: 2056 • ACR Convergence 2022

    Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis

    Takehiro Nakai1, Sho Fukui2, Takahiro Asano3, Futoshi Iwata4, Hiroki Ozawa5, Satoshi Kawaai4, Yukihiko Ikeda1, Hiromichi Tamaki1, Mitsumasa Kishimoto6, Kenichi YAMAGUCHI7 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Kyorin University Hospital, Tokyo, Japan, 3St. Luke's International Hospital, Chuo City Tokyo, Japan, 4St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 5Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, 6Kyorin University School of Medicine, Yokohama, Japan, 7St.Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
  • Abstract Number: 2101 • ACR Convergence 2022

    Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study

    Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL

    Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
  • Abstract Number: 1998 • ACR Convergence 2022

    Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical Activity, and Stress Management in Patients with Rheumatoid Arthritis: A Randomized Controlled Trial

    Wendy Walrabenstein1, Carlijn Wagenaar1, Marike van der Leeden2, Franktien Turkstra1, Jos Twisk3, Maarten Boers4, Henriët van Middendorp5, Peter Weijs2 and Dirkjan van Schaardenburg2, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Epidemiology and Biostatistics, Amsterdam, Netherlands, 4Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 5Leiden University, Leiden, Netherlands

    Background/Purpose: Lifestyle factors have been associated with the development and progression of rheumatoid arthritis. Interventions involving whole food plant-based diets (1-3), physical activity (4) or…
  • Abstract Number: 1487 • ACR Convergence 2022

    Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

    James Krueger1, Kilian Eyerich2, Dennis McGonagle3, Carrie Greving4, Kacey Sachen4, Deepa Hammaker4, Phuc Bao4, Eilyn Lacy4, M. Merle Elloso5, Yevgeniya Orlovsky5, Iain B McInnes6 and Anne Fourie7, 1The Rockefeller University, New York, NY, 2Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, 3University of Leeds, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 5Janssen Research and Development, LLC, Spring House, PA, 6Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 7Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA

    Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
  • Abstract Number: 2088 • ACR Convergence 2022

    Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort

    Jacob N. Hunnicutt1, Mary E. Georgiou2, Anna Richards2, Holly Quasny3, Laurence S Magder4, Daniel W. Goldman5 and Michelle Petri5, 1GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, 2GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 3GlaxoSmithKline, Clinical Sciences, Research Triangle Park, NC, 4University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 5Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…
  • Abstract Number: 2112 • ACR Convergence 2022

    Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Christopher Ritchlin1, Philip J Mease2, Wolf-Henning Boehncke3, John Tesser4, Soumya Chakravarty5, Emmanouil Rampakakis6, May Shawi7, Elena Schiopu8, Joseph Merola9, Iain B McInnes10 and Atul Deodhar11, 1Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 2Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 3Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, 4Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 5Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 9Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 10Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
  • Abstract Number: 2097 • ACR Convergence 2022

    Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis

    David Kellner1, Jonathan Zuckerman1, Jennifer Grossman2 and Maureen McMahon2, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Renal biopsy has long been the gold standard for diagnosis of lupus nephritis (LN), and pathologic features on biopsy are commonly used to guide…
  • Abstract Number: 2065 • ACR Convergence 2022

    Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares

    Diane Zisa1, Jeffrey Zhang-Sun1, Paul Christos2 and Kyriakos Kirou1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine/New York-Presbyterian, New York, NY

    Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
  • Abstract Number: 2038 • ACR Convergence 2022

    Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome

    Sarah Pringle1, Fred Spijkervet1, Arjan Vissink2, Hendrika Bootsma1 and Frans Kroese1, 1University Medical Center Groningen, Groningen, Netherlands, 2UMCG, Leek, Netherlands

    Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…
  • Abstract Number: 2040 • ACR Convergence 2022

    Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, R. Hal Scofield2, Kiely Grundahl1, Lida Radfar2, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
  • « Previous Page
  • 1
  • …
  • 423
  • 424
  • 425
  • 426
  • 427
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology